Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung

Reuters

Feb 10

Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung

Enanta Pharmaceuticals Inc. wird präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung von mastzellvermittelten Typ-2-Immunerkrankungen, auf der Jahrestagung der American Academy of Allergy, Asthma & Immunology (AAAAI) vom 27. Februar bis 2. März 2026 in Philadelphia, PA präsentieren. Die Posterpräsentationen finden am 27. Februar 2026 von 14:45 bis 15:45 Uhr EST statt. Abstracts sind im Online-Supplement der Journal of Allergy and Clinical Immunology (JACI) Plattform verfügbar: https://www.jacionline.org/. Weitere Informationen zur AAAAI 2026 sind hier verfügbar: https://annualmeeting.aaaai.org/. Die Poster werden nach den Präsentationen am 27. Februar 2026 auf der Website von Enanta veröffentlicht: https://www.enanta.com/publications/.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210569136) on February 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610642350"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610642350\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610642350?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610642350","market":"fut","top_or_hot":-1,"title":"Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENTA\">Enanta Pharmaceuticals Inc.</a> wird präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung von mastzellvermittelten Typ-2-Immunerkrankungen, auf der Jahrestagung der American Academy of Allergy, Asthma &amp; Immunology (AAAAI) vom 27. Februar bis 2. März 2026 in Philadelphia, PA präsentieren. Die Posterpräsentationen finden am 27. Februar 2026 von 14:45 bis 15:45 Uhr EST statt. Abstracts sind im Online-Supplement der Journal of Allergy and Clinical Immunology (JACI) Plattform verfügbar: https://www.jacionline.org/. Weitere Informationen zur AAAAI 2026 sind hier verfügbar: https://annualmeeting.aaaai.org/. Die Poster werden nach den Präsentationen am 27. Februar 2026 auf der Website von Enanta veröffentlicht: https://www.enanta.com/publications/.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210569136) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ENTA\">Enanta Pharmaceuticals Inc.</a> wird präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung von mastzellvermittelten Typ-2-Immunerkrankungen, auf der Jahrestagung der American Academy of Allergy, Asthma &amp; Immunology (AAAAI) vom 27. Februar bis 2. März 2026 in Philadelphia, PA präsentieren. Die Posterpräsentationen finden am 27. Februar 2026 von 14:45 bis 15:45 Uhr EST statt. Abstracts sind im Online-Supplement der Journal of Allergy and Clinical Immunology (JACI) Plattform verfügbar: https://www.jacionline.org/. Weitere Informationen zur AAAAI 2026 sind hier verfügbar: https://annualmeeting.aaaai.org/. Die Poster werden nach den Präsentationen am 27. Februar 2026 auf der Website von Enanta veröffentlicht: https://www.enanta.com/publications/.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210569136) on February 10, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL32JFDb:1","article_id":"2610642350","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610642350","pubTimestamp":1770724828,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire  on February 10, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENTA":"Enanta Pharmaceuticals Inc."},"translate_title":"Enanta Pharmaceuticals在AAAAI年会上展示EDP-978的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENTA":0.9},"content_text":"Enanta Pharmaceuticals präsentiert präklinische Daten zu EDP-978 auf der AAAAI-Jahrestagung\n    \n\nEnanta Pharmaceuticals Inc. wird präklinische Daten zu EDP-978, einem KIT-Inhibitor zur Behandlung von mastzellvermittelten Typ-2-Immunerkrankungen, auf der Jahrestagung der American Academy of Allergy, Asthma & Immunology (AAAAI) vom 27. Februar bis 2. März 2026 in Philadelphia, PA präsentieren. Die Posterpräsentationen finden am 27. Februar 2026 von 14:45 bis 15:45 Uhr EST statt. Abstracts sind im Online-Supplement der Journal of Allergy and Clinical Immunology (JACI) Plattform verfügbar: https://www.jacionline.org/. Weitere Informationen zur AAAAI 2026 sind hier verfügbar: https://annualmeeting.aaaai.org/. Die Poster werden nach den Präsentationen am 27. Februar 2026 auf der Website von Enanta veröffentlicht: https://www.enanta.com/publications/.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enanta Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260210569136) on February 10, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}